CoChat

The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials

Open access
McIntyre, RS, Harrison, J, Loft, H, Jacobson, W, Olsen, CK · 2016 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Management of cognitive deficits in Major Depressive Disorder (MDD) remains an important unmet need. This meta-analysis evaluated the effects of vortioxetine on cognition in patients with MDD. METHODS: Random effects meta-analysis was applied to three randomized, double-blind, placebo-controlled 8-week trials of vortioxetine (5-20mg/day) in MDD, and separately to two duloxetine-referenced trials. The primary outcome measure was change in Digit Symbol Substitution Test (DSST) score. Standardized effect sizes (SES) versus placebo (Cohen's d ) were used as input. Path analysis was employed to determine the extent to which changes in DSST were mediated independently of a change in Montgomery-Åsberg Depression Rating Scale (MADRS) score. Meta-analysis was applied to MADRS-adjusted and -unadjusted SES values. Changes on additional cognitive tests were evaluated (source studies only). RESULTS: Before adjustment for MADRS, vortioxetine separated from placebo on DSST score (SES 0.25-0.48; nominal p < 0.05) in all individual trials, and statistically improved DSST performance versus placebo in meta-analyses of the three trials (SES = 0.35; p < 0.0001) and two duloxetine-referenced trials (SES = 0.26; p = 0.001). After adjustment for MADRS, vortioxetine maintained DSST improvement in one individual trial ( p = 0.001) and separation from placebo was maintained in meta-analyses of all three trials (SES = 0.24; p < 0.0001) and both duloxetine-referenced trials (SES 0.19; p = 0.01). Change in DSST with duloxetine failed to separate from placebo in individual trials and both meta-analyses. Change in DSST statistically favored vortioxetine versus duloxetine after MADRS adjustment (SES = 0.16; p = 0.04). CONCLUSIONS: Vortioxetine, but not duloxetine, significantly improved cognition, independent of depressive symptoms. Vortioxetine represents an important treatment for MDD-related cognitive dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyw055

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Total, direct, and indirect effects of vortioxetine and duloxetine on Digital Symbol Substitution Test adjusted for change from baseline in MADRS score (path analysis). *p < 0.05, **p < 0.01, ***p < 0.001 vs placebo. Numbers above bars are standardized total effect size versus placebo. P-values refer to results from unmediated ANCOVA model that did not include change in MADRS. Meta 3 studies: meta-analysis based on Mahableshwarkar et al. (2015), McIntyre et al. (2014), and Katona et al. (2012). Meta 2 studies: meta-analysis based on Mahableshwarkar et al. (2015) and Katona et al. (2012). Indirect effect: correlated with MADRS; direct effect: not correlated with MADRS. ANCOVA, analysis of covariance; DUL, duloxetine; MADRS, Montgomery-Åsberg Depression Rating Scale; VOR, vortioxetine.
Figure 1. Total, direct, and indirect effects of vortioxetine and duloxetine on Digital Symbol Substitution Test adjusted for change from baseline in MADRS score (path analysis). *p < 0.05, **p < 0.01, ***p < 0.001 vs placebo. Numbers above bars are standardized total effect size versus placebo. P-values refer to results from unmediated ANCOVA model that did not include change in MADRS. Meta 3 studies: meta-analysis based on Mahableshwarkar et al. (2015), McIntyre et al. (2014), and Katona et al. (2012). Meta 2 studies: meta-analysis based on Mahableshwarkar et al. (2015) and Katona et al. (2012). Indirect effect: correlated with MADRS; direct effect: not correlated with MADRS. ANCOVA, analysis of covariance; DUL, duloxetine; MADRS, Montgomery-Åsberg Depression Rating Scale; VOR, vortioxetine.CC BY · PubMed Central
Figure 2. Change in DSST (number of correct symbols; SES versus placebo) from baseline to 8 weeks after adjustment for change in MADRS total score. Data are full analysis set (FAS), ANCOVA, last observation carried forward (LOCF). ANCOVA, analysis of covariance; CI, confidence interval; DSST, Digital Symbol Substitution Test; DUL, duloxetine; MADRS, Montgomery-Åsberg Depression Rating Scale; PBO, placebo; SES, standardized effect size; VOR, vortioxetine.
Figure 2. Change in DSST (number of correct symbols; SES versus placebo) from baseline to 8 weeks after adjustment for change in MADRS total score. Data are full analysis set (FAS), ANCOVA, last observation carried forward (LOCF). ANCOVA, analysis of covariance; CI, confidence interval; DSST, Digital Symbol Substitution Test; DUL, duloxetine; MADRS, Montgomery-Åsberg Depression Rating Scale; PBO, placebo; SES, standardized effect size; VOR, vortioxetine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1097/01.ede.0000147107.76079.07 · DOI · Paper page

Cited by

See all 187

Metadata

Authors
McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C.
Corresponding author
McIntyre, RS
Venue
International Journal of Neuropsychopharmacology
Published
2016-06-15
Volume
19
Issue
10
Pages
pyw055
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2436735416
Cited by
185
References
44
Citations by year
2026: 10 · 2025: 12 · 2024: 17 · 2023: 14 · 2022: 25 · 2021: 23 · 2020: 20 · 2019: 27 · 2018: 17 · 2017: 15 · 2016: 5
FWCI
2.45
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • HighWire Press Open Archive (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • Takeda Pharmaceuticals U.S.A.
  • H. Lundbeck A/S
  • University of California, San Diego
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
vortioxetine, major depressive disorder, cognitive function, cognitive impairment, duloxetine, Digit Symbol Substitution Test, neuropsychological outcomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.